18 F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор)

This review summarizes recent advances in diagnostics of oncology diseases by nuclear imaging techniques using labeled glucose derivatives as radiopharmaceuticals (RPs). A major attention is focused on 2-[ 18 F]fluoro-2-deoxy-D-glucose ( 18 F-FDG), fluorinated glucose analog labeled with fluorine-18 ( T 1/2 , 110 min). This unique radiotracer is applied in 90% of all clinical studies by positron emission tomography (PET). The general aspects of the 18 F-FDG synthesis and modern automation platforms ensuring generation of dozen clinical doses of radiotracers for human PET studies are described. Various applications of 18 F-FDG in PET imaging of various types of tumor are discussed. In addition, the potential of recently developed derivatives of glucose labeled with other radionuclides ( 68 Ga, 123 I, 99m Tc, 188 Re) as tumor seeking agents for PET and single-photon emission computer tomography (SPECT) is assessed.